COMP <GO>
EXEL vs HALO // FORWARD P/E MULTIPLE
Exelixis Inc. (NASDAQ) VS. Halozyme Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EXEL 11
— HALO 2
▲ FORWARD P/E MULTIPLE LEADER: EXEL
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
forward-pe
19.5x
LAST: $130.91 (-0.21%) • MKT CAP: $14.89B
forward-pe
39.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. HALO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | HALO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.60% | +12.40 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 18.00% | +17.10 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 35.6x | -17.20 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 4.33% | +1.01 | EXEL | /fcf-yield <GO> |
| Operating Margin | 37.60% | 33.60% | +4.00 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 22.70% | +11.00 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 37.60% | -30.60 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 5.11 | +11.53 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 79.0 | -15.70 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.88 | +0.08 | EXEL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 19.5x | 39.5x | -20.00 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $14.89B | $1.51B | EXEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | HALO REV | EXEL GROSS % | HALO GROSS % | EXEL FCF | HALO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $1.40B | 96.4% | 83.6% | $875.8M | $644.6M |
| FY 2024 | $2.17B | $1.02B | 96.5% | 84.3% | $671.5M | $468.4M |
| FY 2023 | $1.83B | $829.3M | — | — | $251.0M | $351.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
HALO // BETA 0.88